• >
  • Публикации
  • >
  • DISLIPIDEMIK GIPERTENZIYADA POLIPILL TERAPIYASI: KARDIOVASKULYAR XAVFNI KAMAYTIRISH VA ORGANOPROTEKSIYANING YANGI IMKONIYATLARI

DISLIPIDEMIK GIPERTENZIYADA POLIPILL TERAPIYASI: KARDIOVASKULYAR XAVFNI KAMAYTIRISH VA ORGANOPROTEKSIYANING YANGI IMKONIYATLARI

  • Авторы:Abdukomilov A.M, Fayzullayeva Shaxlo Sodiqjon qizi, Xamidullayeva Gulnoza Abdusattorovna, Abdullayeva Guzal Jalolovna, Yusupova Hafiza Furqatovna,Xonberdiyeva Nargiza Ravshan qizi
  • Дата публикации:September 23, 2026
  • Тип:
  • DOI: 10.64156/mju.9685
  • Том / № Выпуска:Том 1 №5 (2026)

Аннотация

Annotatsiya. Maqsad: Arterial gipertenziya va dislipidemiyaga ega, SCORE2 shkalasi bo’icha yuqori va juda yuqori yurak-qon tomir xavfli bemorlarda lizinopril/amlodipin/rozuvastatin tarkibli polipill va erkin kombinatsiyalangan terapiyaning samaradorligini qiyosiy baholash.

Material va usullar: Tadqiqotga 40–75 yoshdagi 119 nafar arterial gipertenziya va dislipidemiyali bemor jalb qilindi. Bemorlar ikki guruhga randomizatsiya qilindi: 1-guruh (n=60) lizinopril/amlodipin/rozuvastatin tarkibli polipill, 2-guruh (n=59) esa perindopril/amlodipin va rozuvastatinning erkin kombinatsiyasini qabul qildi. Ko’rsatkichlar dastlabki, 12 haftalik va 6 oylik davrlarda baholandi.

Natijalar: 6 oylik davolash yakunida polipill guruhida arterial bosim, PZLP-XS, umumiy xolesterin, ApoB va aterogenlik indeksining pasayishi nazorat guruhiga nisbatan ishonchli yuqori bo’ldi. Maqsadli AB darajasiga erishish: polipill 81% vs nazorat 57%. SCORE2 bo’icha kardiovaskulyar xavf polipill guruhida 43,9%, nazorat guruhida 21,6% ga kamaydi (p<0,001). Albumin/kreatinin nisbati polipill guruhida 127 dan 36 mg/g gacha kamaydi.

Xulosa: Polipill terapiyasi yuqori va juda yuqori kardiovaskulyar xavfli bemorlarda erkin kombinatsiyaga nisbatan arterial bosim va lipid ko’rsatkichlarini samaraliroq nazorat qiladi, organoprotektiv ta’sir ko’rsatadi hamda umumiy kardiovaskulyar xavfni sezilarli kamaytiradi.

Kalit so’zlar: arterial gipertenziya, dislipidemiya, polipill, SCORE2, yurak-qon tomir xavfi, arterial qattiqlik, organoproteksiya.

Abstract. Objective: To comparatively evaluate the efficacy of a fixed-dose combination (polypill) containing lisinopril/amlodipine/rosuvastatin versus free combination therapy in patients with arterial hypertension and dyslipidemia at high and very high cardiovascular risk according to SCORE2.

Material and Methods: 119 patients aged 40–75 years were randomized into two groups: Group 1 (n=60) received the polypill (lisinopril/amlodipine/rosuvastatin); Group 2 (n=59) received free combination (perindopril/amlodipine + rosuvastatin). Parameters were assessed at baseline, 12 weeks, and 6 months.

Results: At 6 months, the polypill group showed significantly greater reductions in blood pressure, LDL-C, total cholesterol, ApoB, and atherogenicity index. Target BP achieved: 81% vs 57%. SCORE2 risk decreased by 43.9% vs 21.6% (p<0.001). Albumin/creatinine ratio decreased from 127 to 36 mg/g in the polypill group.

Conclusion: Polypill therapy with lisinopril/amlodipine/rosuvastatin provides superior blood pressure and lipid control, demonstrates organoprotective effects, and significantly reduces overall cardiovascular risk compared to free combination therapy.

Keywords: arterial hypertension, dyslipidemia, polypill, SCORE2, cardiovascular risk, arterial stiffness, organoprotection.

Аннотация. Цель: Сравнительная оценка эффективности фиксированной дозировой комбинации (полипилль) лизиноприл/амлодипин/розувастатин и свободной комбинации у больных высокого и очень высокого сердечно-сосудистого риска по SCORE2.

Материал и методы: 119 больных 40–75 лет рандомизированы на 2 группы: 1-я (n=60) – полипилль; 2-я (n=59) – свободная комбинация. Контрольные визиты: исходно, через 12 недель и 6 месяцев.

Результаты: Через 6 месяцев в группе полипилля отмечено достоверно большее снижение АД, ХНП-ЛП, общего ХС, ApoB и индекса атерогенности. Целевого АД достигли 81% vs 57%. Риск SCORE2 снизился на 43,9% vs 21,6% (p<0,001). Альбумин/креатинин: 127→36 мг/г в группе полипилля.

Заключение: Полипилльная терапия обеспечивает более эффективный контроль АД и липидных показателей, оказывает органопротективное действие и значительно снижает общий сердечно-сосудистый риск.

Ключевые слова: артериальная гипертензия, дислипидемия, полипилль, SCORE2, сердечно-сосудистый риск, артериальная жёсткость, органопротекция.

 

60

References

  1. Stark B.A. et al. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990–2023. J Am Coll Cardiol. 2025;86(22):2167–2243. https://doi.org/10.1016/j.jacc.2025.08.015.
  2. World Health Organization. Prevalence of Risk Factors for Noncommunicable Diseases in the Republic of Uzbekistan, 2019. WHO/EURO:2022-6795-46561-67569. Geneva: WHO; 2022.
  3. GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries, 1990–2021. Lancet. 2024;403(10440):2162–2203. https://doi.org/10.1016/S0140-6736(24)00933-4.
  4. Wang W. et al. Global Burden of Disease Study 2019: metabolic risk factors are the leading drivers of ischemic heart disease. Cell Metab. 2021;33(10):1943–1956.e2. https://doi.org/10.1016/j.cmet.2021.08.005.
  5. Williams R.R., Hunt S.C., Hopkins P.N. et al. Familial dyslipidemic hypertension: evidence from 58 Utah families. JAMA. 1988;259(24):3579–3586. https://doi.org/10.1001/jama.1988.03720240041032.
  6. Kannel W.B. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens. 2000;14(2):83–90.
  7. Burnier M. Drug adherence in hypertension. Pharmacol Res. 2017;125:142–149. https://doi.org/10.1016/j.phrs.2017.08.015.
  8. Memon R.A. et al. Effect of the polypill on adherence and prevention of cardiovascular diseases: a meta-analysis of randomized controlled trials. Cureus. 2023;15(1):e34134. https://doi.org/10.7759/cureus.34134.
  9. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. https://doi.org/10.1093/eurheartj/ehy339.
  10. Kónyi A., Sárszegi Z., Hild G., Gaszner B. Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients. J Comp Eff Res. 2016;5(4):355–364. https://doi.org/10.2217/cer-2016-0003.
  11. Mach F. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111–188. https://doi.org/10.1093/eurheartj/ehz455.
  12. Dahlöf B. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required (ASCOT-BPLA). Lancet. 2005;366(9489):895–906. https://doi.org/10.1016/S0140-6736(05)67185-1.
  13. Sever P.S. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients (ASCOT-LLA). Lancet. 2003;361(9364):1149–1158. https://doi.org/10.1016/S0140-6736(03)12948-0.
  14. Webster R. et al. Effectiveness of fixed dose combination medication ('polypills') compared with usual care: individual patient data meta-analysis of 3140 patients. Int J Cardiol. 2016;205:147–156. https://doi.org/10.1016/j.ijcard.2015.12.015
  15. Roshandel G., Khoshnia M., Poustchi H. et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran). Lancet. 2019;394(10199):672–683. https://doi.org/10.1016/S0140-6736(19)31791-X.
Show All References
Статистика публикации
  • Скачано:3
  • Просмотрено:60
  • References15
Скачать файлОткрыть PDF в браузере
Поделиться
Похожие публикации

КОМПЛЕКСНАЯ ОЦЕНКА ФИЗИЧЕСКОГО РАЗВИТИЯ ДЕТЕЙ ДОШКОЛЬНОГО ВОЗРАСТА С ИСПОЛЬЗОВАНИЕМ АНТРОПОМЕТРИИ И БИОЭЛЕКТРИЧЕСКОГО ИМПЕДАНСНОГО АНАЛИЗА

ЮРАК ИШЕМИК КАСАЛЛИГИДА ҚЎЛЛАНИЛАДИГАН ДОРИ ВОСИТАЛАРИНИНГ САМАРАДОРЛИГИ КЎРСАТКИЧЛАРИНИ БАҲОЛАШ

МЕТАБОЛИК СИНДРОМ ОҚИБАТИДА ЮРАК-ҚОН ТОМИР КАСАЛЛИКЛАРИ РИВОЖЛАНИШИДА ЛЕПТИН РЕЦЕПТОРИ ГЕНИ (LEPR, Q223R, RS1137101) ПОЛИМОРФИЗМИНИНГ АҲАМИЯТИ